ABSTRACT
Aim: To evaluate E-cadherin expression in various clinical and pathological prognostic scenarios to determine its significance in the development of molecular subtypes of invasive ductal breast cancer.
Materials and Methods: A comprehensive morphological and immunohistochemical study of 80 cases of invasive ductal carcinoma (IDC) was conducted to determine the molecular phenotype. The expression of E-cadherin, ER, PR receptors, c-erbB2, and Ki-67 was evaluated according to the manufacturer’s standardized protocols using appropriate positive and negative controls. The degree of tumor malignancy was determined using the modified Scarff-BloomRichardson system. Semi-quantitative assessment of E-cadherin expression was performed using the Qureshi scale. Pearson’s criterion was used for statistical analysis. Differences were considered statistically significant at p < 0.05.
Results: Low E-cadherin expression was associated with stage 3, pT3, and G2/G3 grades of IDBC malignancy, confirming its unfavorable prognostic significance and correlation with the molecular profile. High E-cadherin expression was characteristic of ER-positive luminal A tumors, regardless of menopause, indicating
a regulatory role for ER expression. The low proliferative activity of luminal IDBC cells was explained by high E-cadherin expression, which increased adhesive properties. Low E-cadherin expression is also a prognostic marker for TNBC.
Conclusions: E-cadherin is a potent tumor suppressor in breast cancer. Its role in disease progression is confirmed by the correlation between partial or complete loss of E-cadherin expression and poor prognosis for patients.
KEY WORDS: E-cadherin expression, morphological and immunohistochemical study, invasive ductal breast cancer, molecular phenotype

Nonsteroidal anti-inflammatory drugs (NSAIDs), used in the treatment of numerous diseases, can cause a number of side effects, the main of which is an ulcerogenic effect on the mucous membranes of the gastrointestinal tract. NSAIDs can also cause side effects in the hepato-biliary, cardiovascular, excretory systems, affect the functioning of the liver and lungs [1]. The mechanism of action of NSAIDs is based on the inhibition of the activity of cyclooxygenase (COX), which exists in two main isoforms COX-1 and COX-2, differ structurally and functionally [2, 3]. COX-1 is a constitutive isoform that is expressed throughout the body and synthesizes prostaglandins involved in numerous physiological processes. In particular, with the participation of COX-1, prostaglandins are formed. They regulate the secretion of hydrochloric acid and stimulate the formation of protective mucus in the stomach, influence the process of proliferation and intercellular integration in various organs, regulate vascular homeostasis, platelet aggregation, and kidney function. COX-2 is an inducible form of the enzyme, which expression increases during inflammation, ensuring the synthesis of relatively large concentrations of prostaglandins, that act as the inflammation mediators [4, 5]. Considering the numerous side effects of currently existing NSAIDs, the development of new anti-inflammatory drugs devoid of side effects is actively underway. In this sense, the compounds capable of simultaneous inhibiting the cyclooxygenase and lipoxygenase (LOX) pathways of arachidonic acid metabolism are of significant interest. Dual-acting COX/LOX inhibitors could provide multiple...